Chaitanya Bandlamudi

20PUBLICATIONS
278CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersCancer geneticsNatural language processing
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Mar 27, 2026
POLQ-driven repair scars shape the immunogenic landscape of homologous recombination-deficient pancreatic cancer.

Wungki Park, Shigeaki Umeda, Marc Hilmi

|Mar 26, 2026
Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial.

Wungki Park, Catherine A O'Connor, Joanne F Chou

|Mar 25, 2026
A Phase II Trial of Olaparib plus Pembrolizumab in Patients with Recurrent Copy Number-High/p53-Abnormal Endometrial Cancer.

Maria M Rubinstein, Jennifer Y Ge, Qin Zhou

|Mar 04, 2026
Homologous recombination deficiency and hemizygosity drive resistance in breast cancer.

Anton Safonov, Minna Lee, David N Brown

|Jan 28, 2026
Genomic Enrichment and Functional Impact of TP53 and CYLD Alterations in Recurrent and Metastatic HPV-Associated Head and Neck Cancer.

Manu Prasad, Alex T Cheng, Marcel Mayer

|Sep 15, 2025
Pembrolizumab and Olaparib (POLAR) Maintenance Therapy in Metastatic Pancreatic Cancer With or Without Homologous Repair Deficiency: A Biomarker Selected Phase II Trial.

Wungki Park, Catherine O'Connor, Joanne Chou

Pageof 4

Frequent Collaborators

14 joint publications

Michael F Berger

8 joint publications

Daniel Muldoon

7 joint publications

Eileen O'Reilly

7 joint publications

Wungki Park